Trial Profile
Phase II selection design trial of concurrent chemotherapy + cetuximab vs. chemotherapy then cetuximab in advanced non-small cell lung cancer (NSCLC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
- 31 Oct 2012 Actual end date Jul 2011 added as reported by ClinicalTrials.gov.
- 10 Aug 2005 New trial record.